The Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd, known as Biovac or The Biovac Institute, is a Cape Town-based biopharmaceutical company founded in 2003 as a public-private partnership with the South African government. It focuses on developing and manufacturing vaccines to enhance Africa's self-reliance in vaccine production and supply.
Biovac supplies approximately 80% of South Africa's routine pediatric vaccines and has delivered over 450 million doses across southern Africa since inception. Its cGMP-compliant facilities in Cape Town support end-to-end processes including bacterial fermentation, purification, formulation, vial and syringe filling, and quality control testing. Key products include hexavalent and pneumococcal conjugate vaccines, produced in partnership with Sanofi Pasteur and Pfizer.
The company is expanding with Africa's first end-to-end multi-vaccine facility, backed by EIB, IFC, and EU funding, to produce oral cholera, polio, pneumococcal, and meningitis vaccines by 2028, targeting 30-40 million doses annually for regional needs via UNICEF and Gavi.
Also known as The Biovac Institute.
chemXplore tracks 1 project involving Biovac, of which one is active.
Biovac's role on them: Owner.
1 new construction.
€75M quasi‑equity and $20M senior loan finance a South African end‑to‑end multi‑vaccine plant (2028) to produce cholera, polio, pneumonia and meningitis vaccines (30–40M doses/yr); 340 skilled, 7,000 indirect jobs.
By country, the most active first. active / all projects
